402 related articles for article (PubMed ID: 11585970)
1. Optimizing the use of irinotecan in colorectal cancer.
Cunningham D; Maroun J; Vanhoefer U; Van Cutsem E
Oncologist; 2001; 6 Suppl 4():17-23. PubMed ID: 11585970
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
[TBL] [Abstract][Full Text] [Related]
3. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
Van Cutsem E; Verslype C; Tejpar S
Semin Oncol; 2005 Feb; 32(1):43-51. PubMed ID: 15726505
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan in the treatment of colorectal cancer: clinical overview.
Vanhoefer U; Harstrick A; Achterrath W; Cao S; Seeber S; Rustum YM
J Clin Oncol; 2001 Mar; 19(5):1501-18. PubMed ID: 11230497
[TBL] [Abstract][Full Text] [Related]
5. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine/irinotecan combination regimens in colorectal cancer.
Kerr DJ
Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):27-9. PubMed ID: 12014865
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.
Borner MM; Bernhard J; Dietrich D; Popescu R; Wernli M; Saletti P; Rauch D; Herrmann R; Koeberle D; Honegger H; Brauchli P; Lanz D; Roth AD;
Ann Oncol; 2005 Feb; 16(2):282-8. PubMed ID: 15668285
[TBL] [Abstract][Full Text] [Related]
8. Current status of capecitabine in the treatment of colorectal cancer.
Rothenberg ML
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
[TBL] [Abstract][Full Text] [Related]
9. The role of new agents in the treatment of colorectal cancer.
Folprecht G; Köhne CH
Oncology; 2004; 66(1):1-17. PubMed ID: 15031593
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
[TBL] [Abstract][Full Text] [Related]
12. [The new chemotherapy of colorectal cancers].
Taïeb J; Boige V; Ducreux M
Presse Med; 2002 Jan; 31(3):132-8. PubMed ID: 11859739
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Ducreux M; Köhne CH; Schwartz GK; Vanhoefer U
Ann Oncol; 2003; 14 Suppl 2():ii17-23. PubMed ID: 12810453
[TBL] [Abstract][Full Text] [Related]
14. Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
Cunningham D; James RD
Eur J Cancer; 2001 May; 37(7):826-34. PubMed ID: 11313169
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.
Jordan K; Kellner O; Kegel T; Schmoll HJ; Grothey A
Clin Colorectal Cancer; 2004 May; 4(1):46-50. PubMed ID: 15207020
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
17. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?].
Carnaghi C; Zucali P; Garassino I
Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298
[TBL] [Abstract][Full Text] [Related]
18. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
19. [Systemic treatment of colorectal cancers--factual standards and perspectives].
Miron L
Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):752-8. PubMed ID: 14756014
[TBL] [Abstract][Full Text] [Related]
20. Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?
Aguado C; García-Paredes B; Sotelo MJ; Sastre J; Díaz-Rubio E
World J Gastroenterol; 2014 May; 20(20):6092-101. PubMed ID: 24876731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
